Table 1.
Baseline soluble protein levels and ratios to baseline in patients stratified by clinical response (RECIST and Choi criteria)
| Soluble protein and time point | RECIST | Choi criteria | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Disease control | No disease control | Rank sum P-value |
Responders | Non-responders | Rank sum P-value |
|||||
| Median | n | Median | n | Median | n | Median | n | |||
| VEGF-A | ||||||||||
| Baseline, pg/mL | 108.7 | 14 | 46.6 | 13 | 0.0332* | 92.7 | 17 | 51.9 | 9 | 0.0250* |
| C2D1:D1 | 0.861 | 14 | 1.132 | 8 | 0.0352* | 0.861 | 14 | 1.105 | 6 | 0.0757 |
| C2D28:D1 | 1.426 | 13 | 3.617 | 6 | 0.0874 | 1.639 | 12 | 3.63 | 3 | 0.5363 |
| VEGF-C | ||||||||||
| Baseline, pg/mL | 1,416.5 | 14 | 741.5 | 13 | 0.0027* | 1058 | 17 | 774.8 | 9 | 0.0662 |
| C1D28:D1 | 0.529 | 13 | 0.806 | 9 | 0.0708 | 0.595 | 15 | 1.121 | 7 | 0.0319* |
| C2D1:D1 | 0.596 | 14 | 0.947 | 8 | 0.0197* | 0.5636 | 14 | 0.839 | 6 | 0.0256* |
| sVEGFR-3 | ||||||||||
| C1D14:D1 | 0.352 | 14 | 0.622 | 12 | 0.031* | 0.4857 | 17 | 0.613 | 9 | 0.4580 |
Disease control (RECIST) defined as complete or partial response or stable disease > 12 weeks; no disease control defined as stable disease < 12 weeks or progressive disease
*Significant at the 0.05 level
C, cycle; D, day